AlphaIndicator BIOA 20170209 PDF

BIOALPHA HOLDINGS (BIOHLDG-KU)
Pharma. & Med. Research / Pharmaceuticals / Pharmaceuticals DETAILED STOCK REPORT

Report Date: 09 February 2017
Last Close Avg Daily Vol 52-Week High Trailing PE Annual Div ROE LTG Forecast 1-Mo Return
0.23 (MYR) 6.7M 0.33 15.7 -- 9.6% -- 4.7%
08 February 2017 Market Cap 52-Week Low Forward PE Dividend Yield Annual Rev Inst Own 3-Mo Return
MALAYSIA Exchange
180M 0.20 22.5 0.0% 41M 22.3% -5.1%
AVERAGE SCORE
NEUTRAL OUTLOOK: BIOHLDG's current Score Averages
score is relatively in-line with the market. Pharmaceuticals Group: 6.6 Small Market Cap: 5.2
Pharma. & Med. Research Sector: 5.6 FBM KLCI Index: 6.7
Average Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive KOTRA 5 4 4 5 7
PHARMA 6 6 6 5 6
Neutral BIOHLDG 5 2 4 4 4
HOVID 4 4 3 3 3
Negative
RHONEMA NR NR NR NR NR
FEB-2014 FEB-2015 FEB-2016 FEB-2017
HIGHLIGHTS THOMSON REUTERS I/B/E/S MEAN

- The score for Bioalpha Holdings last changed from 5 to 4 on
22/01/17. Buy Mean recommendation from all analysts covering
1 Analyst the company on a standardized 5-point scale.
- The recent change in the Average Score was due to a decline
in the Price Momentum, Fundamental, and Risk component
scores. Strong
Sell Reduce Hold Buy
Buy
PRICE AND VOLUME CHARTS

1-Year Return: -9.4% 5-Year Return: --
BUSINESS SUMMARY
Bioalpha Holdings Berhad is an investment holding company. The Company operates through manufacturing and sale of semi-finished and finished
health supplement products segment. Through its subsidiaries, the Company manufactures a range of health supplement products in the form of
powder, liquid, teabag, capsule and tablet under its house brands, as well as on an original design manufacturing. Its health supplement products
consists of processed herbs, formulated ingredients, functional foods, as well as herbal and nonherbal supplements, which offer a range of health
benefits, including general health maintenance. Its subsidiaries include Bioalpha International Sdn. Bhd., which is a manufacturer, importer, exporter,
distributor and trader of nutritional and healthcare products, and Botanical Distribution Sdn. Bhd., which is a supplier, distributor, direct selling agent
wholesaler or retailer of healthcare and nutrition products.
Page 1 of 11
2017 Thomson Reuters. All rights reserved.
INDICATOR COMPONENTS
The AVERAGE SCORE combines the quantitative analysis of five widely-used investment decision making tools: Earnings,
Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally
distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using
alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles.
Additional criteria should always by used to evaluate a stock.
Earnings Fundamental Relative Valuation Risk Price Momentum
PEER ANALYSIS Currency in MYR
PRICE MOMENTUM VALUATION FUNDAMENTAL ANALYSTS

Average Price 1-Mo 3-Mo 1-Yr Market Trailing Forward Dividend Net LTG I/B/E/S # of
Score Ticker (08/02/17) Return Return Return Cap PE PE Yield Margin Forecast Mean Analysts
6 PHARMA 5.17 -1.0% -6.7% -16.2% 1.3B 21.4 20.1 3.9% 2.7% -- Hold 3
8 CCMDBIO 2.18 11.2% 1.4% -17.1% 589M 20.4 -- 3.7% 9.5% -- -- --
9 YSPSAH 2.05 7.9% -4.2% -25.2% 271M 12.6 12.1 3.2% 9.6% -- Buy 1
3 HOVID 0.33 -4.3% -12.0% -28.3% 254M 21.9 16.5 3.0% 8.2% -- Hold 3
4 BIOHLDG 0.23 4.7% -5.1% -9.4% 180M 15.7 22.5 0.0% 20.0% -- Buy 1
7 KOTRA 1.15 8.5% 8.5% 4.5% 153M 37.3 -- -- 2.7% -- -- --
NR RHONEMA 0.92 -2.6% -- -- 153M -- -- -- -- -- -- --
3 SUNZEN 0.25 19.5% 14.0% -12.5% 117M -- -- -- -8.1% -- -- --
9 PLABS 0.25 2.1% 4.3% -5.8% 51M 15.4 -- 2.9% 4.1% -- -- --
1 MGRC 0.51 -1.9% 10.9% -25.0% 50M 28.9 -- -- 16.4% -- -- --
5.6 Average 1.30 4.4% 1.2% -15.0% 312M 21.7 17.8 2.8% 7.2% -- Buy 2
PEER COMPANIES
PHARMA Pharmaniaga RHONEMA Rhone Ma Holdings
CCMDBIO CCM Duopharma Biotech SUNZEN Sunzen Biotech
YSPSAH YSP Southeast Asia Holding PLABS PeterLabs Holdings
HOVID Hovid MGRC Malaysian Genomics Resource
KOTRA Kotra Industries
Page 2 of 11
EARNINGS Currency in MYR
This company does not currently meet the data Earnings Score Averages
requirements to calculate a score for this Pharmaceuticals Group: 5.3 Small Market Cap: 5.0
component. Pharma. & Med. Research Sector: 5.3 FBM KLCI Index: 6.4
Earnings Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive PHARMA 6 5 6 6 6
HOVID 1 6 3 2 2
Neutral BIOHLDG NR NR NR NR NR
KOTRA NR NR NR NR NR
Negative
FEB-2014 FEB-2015 FEB-2016 FEB-2017
EARNINGS INDICATORS
Earnings Surprises Estimate Revisions Recommendation Changes
(33.3% weight) (33.3% weight) (33.3% weight)
BIOHLDG
PHARMA HOVID
PHARMA
HOVID HOVID
BIOHLDG KOTRA BIOHLDG

KOTRA RHONEMA KOTRA
RHONEMA PHARMA
RHONEMA
Last 4 Quarters Last 4 Weeks Last 120 Days

# Positive Surprises (> 2%) 0 # Up Revisions 0 # Broker Upgrades 0
# Negative Surprises (< -2%) 0 # Down Revisions 0 # Broker Downgrades 0
# In-Line Surprises (within 2%) 0 Avg Up Revisions 0.0%
Avg Surprise -- Avg Down Revisions 0.0%
HIGHLIGHTS PRICE TARGET

- Due to a lack of recent analyst activity, no Earnings Rating can be The chart indicates where analysts predict the stock price will be within
calculated for Bioalpha Holdings. The average Earnings Rating for its the next 12 months, as compared to the current price.
Pharmaceuticals industry is 5.3 and the FTSE BURSA MALAYSIA
COMPOSITE index average is 6.4. 0.70 12-Month Price Target
Mean 0.45
- Over the past 90 days, the consensus price target for BIOHLDG has 0.60
High 0.45
decreased notably from 0.52 to 0.45, a loss of -13.5%. 0.50 HIGH
MEAN Low 0.45
- There have been no upward or downward broker recommendation 0.40 LOW
Target vs. Current 100.0%
changes for Bioalpha Holdings over the past 120 days.
0.30 0.22 # of Analysts 1
0.20
Current Price Price Target
Page 3 of 11
EARNINGS PER SHARE

Actuals Estimates
Earnings per share (EPS) is calculated Quarterly NA NA

by dividing a company's earnings by the Mean -- --
number of shares outstanding. Analysts Quarterly data is not available
tend to interpret a pattern of increasing High -- --
earnings as a sign of strength and flat Low -- --
or falling earnings as a sign of
# of Analysts -- --
weakness.
The charts provide a comparison NA NA NA NA

between a company's actual and
estimated EPS, including the high and Actuals Estimates
low forecasts. 0.024
0.021 HIGH Annual 2016 2017

MEAN
LOW Mean 0.010 0.020
0.018
High 0.010 0.020
0.015 Low 0.010 0.020
0.012
0.012 # of Analysts 1 1
0.009
2015 2016 2017
MEAN ESTIMATE TREND ANALYST RECOMMENDATIONS

Q Q Y Y Price Thomson Reuters I/B/E/S Mean: Buy (1 Analyst)
-- -- 2016 2017 Target
Current -- -- 0.010 0.020 0.45
Strong Buy 0
30 Days Ago -- -- 0.010 0.020 0.45 Buy 1
90 Days Ago -- -- 0.015 0.020 0.52 Hold 0
% Change (90 Days) -- -- -33.3% 0.0% -13.5%
Reduce 0
Current Fiscal Year End: 12-16
Next Expected Report Date: 06/03/17 Sell 0
EARNINGS SURPRISES
Comparing a company's actual earnings to the mean expectation of Surprise Detail (Last 6 Periods)
analysts results in a difference referred to as a 'positive' or 'negative'
surprise. Research has shown that when a company reports a Surprise Announce Period End Actual Mean Surprise
surprise, it is often followed by more of the same surprise type. Type Date Date EPS EPS (%)
Surprise Summary (Last 12 Quarters)
Surprise Type Amount Percent There are no earnings surprises during this time period.
Positive Quarters (> 2%) 0 --
Negative Quarters (< -2%) 0 --
In-Line Quarters (within 2%) 0 --
ANNUAL REVENUE
A pattern of increasing sales in Actuals Estimates
conjunction with a rising EPS may
influence a buy recommendation, while 72M
HIGH
2016 2017
flat or falling sales and faltering 63M
MEAN
LOW
earnings may explain a sell Mean 45.7M 65.3M
recommendation. A rising EPS with flat 54M High 45.7M 65.3M
or falling sales may result from
increased cost efficiency and margins, 45M
Low 45.7M 65.3M
rather than market expansion. This Forecasted Growth 53.8% 119.7%
chart shows the sales forecast trend of 36M 29.7M # of Analysts 1 1
all analysts and the highest and lowest
projections for the current and next 27M
2015 2016 2017
fiscal year.
Page 4 of 11
FUNDAMENTAL
NEUTRAL OUTLOOK: Fundamentals relatively Fundamental Score Averages
in-line with the market. Pharmaceuticals Group: 6.4 Small Market Cap: 5.2
Q1 Q2 Q3 Q4
Fundamental Score Trend Peers 2016 2016 2016 2016 Current 3Y Trend
HOVID 10 9 8 8 7
Positive
BIOHLDG 5 7 8 9 6
Neutral PHARMA 9 9 8 8 6
Negative KOTRA 3 2 3 4 3
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 RHONEMA NR NR NR NR NR
2014 2015 2016
FUNDAMENTAL INDICATORS
Profitability Debt Earnings Quality Dividend
(25% weight) (25% weight) (25% weight) (25% weight)
BIOHLD HOVID HOVID
BIOHLD
HOVID PHARM BIOHLD
PHARM
KOTRA KOTRA PHARM
PHARM
HOVID
BIOHLD
KOTRA
RHONE RHONE RHONE KOTRA

RHONE
Revenue Growth 43.4% Current Ratio 5.9 Oper. Cash Yield 0.5% Dividend Growth --
For year over year For interim period For latest 12 months For year over year
ending 09-2016 ending 09-2016 ending 09-2016 ending --
Gross Margin 43.8% Debt-to-Capital 1.2% Accruals -3.1% Dividend Payout 4.7%
For latest 12 months For annual period For latest 12 months For latest 12 months
ending 09-2016 ending 12-2015 ending 09-2016 ending 09-2016
Return On Equity 9.6% Interest Funding 57.3% Days Sales In Inv. 184.2 Dividend Coverage 49.4
For interim period For interim period For annual period For annual period
Net Margin 20.0% Interest Coverage 67.3 Days Sales In Rec. 273.0 Current Div. Yield 0.0%
For latest 12 months For interim period For annual period For latest 12 months
HIGHLIGHTS
- Bioalpha Holdings currently has a relatively neutral Fundamental - Bioalpha Holdings currently has a relatively neutral Fundamental
Rating of 6. The average Fundamental Rating for its Pharmaceuticals Rating of 6. The average Fundamental Rating for its Pharmaceuticals
industry group is 6.4 and the FTSE BURSA MALAYSIA COMPOSITE industry group is 6.4 and the FTSE BURSA MALAYSIA COMPOSITE
index average is 7.0. index average is 7.0.
- The net margin of 20.0% for BIOHLDG is the highest within its - The net margin of 20.0% for BIOHLDG is the highest within its
Pharmaceuticals industry group. Pharmaceuticals industry group.
- The current ratio of 5.9 for BIOHLDG is the highest within its
Pharmaceuticals industry group.
Page 5 of 11
RELATIVE VALUATION
NEGATIVE OUTLOOK: Multiples significantly Relative Valuation Score Averages
above the market or the stock's historic norms. Pharmaceuticals Group: 5.1 Small Market Cap: 5.8
Relative Valuation Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive PHARMA 7 6 6 6 6
HOVID 2 3 3 5 5
Neutral KOTRA 6 6 4 5 4
BIOHLDG 2 3 2 2 2
Negative
FEB-2014 FEB-2015 FEB-2016 FEB-2017
RELATIVE VALUATION INDICATORS

Forward PEG Trailing PE Forward PE
(50% weight) (25% weight) (25% weight)
PHARMA
BIOHLDG
KOTRA
HOVID HOVID
HOVID
PHARMA
BIOHLDG
BIOHLDG KOTRA
PHARMA
RHONEMA RHONEMA KOTRA

RHONEMA
Price to Sales 5.4 Trailing PE 15.7 Forward PE 22.5

5-Yr Average 5.3 5-Yr Average 20.1 5-Yr Average 16.6
Rel. to 5-Yr Avg. 3% Premium Rel. to 5-Yr Avg. 22% Discount Rel. to 5-Yr Avg. 36% Premium
FBM KLCI Index 2.8 FBM KLCI Index 17.4 FBM KLCI Index 17.8
Rel. to FBM KLCI 95% Premium Rel. to FBM KLCI 10% Discount Rel. to FBM KLCI 26% Premium
HIGHLIGHTS
- Bioalpha Holdings currently has a Relative Valuation Rating of 2 which - Bioalpha Holdings currently has a Relative Valuation Rating of 2 which
is significantly below the FTSE BURSA MALAYSIA COMPOSITE is significantly below the FTSE BURSA MALAYSIA COMPOSITE
index average rating of 5.5. index average rating of 5.5.
- BIOHLDG's Price to Sales ratio of 5.4 represents a 3% Premium to its - BIOHLDG's Price to Sales ratio of 5.4 represents a 3% Premium to its
5-year average of 5.3. 5-year average of 5.3.
Page 6 of 11
PRICE TO SALES TRAILING PE

The most recent week's close price divided by the revenue per share. The most recent week's close price divided by the sum of the four most
recently reported quarterly earnings.
Price to Sales: 5.4 Trailing PE: 15.7
5-Year Average: 5.3 5-Year Average: 20.1
FBM KLCI Index Average: 2.8 FBM KLCI Index Average: 17.4
Pharmaceuticals Group Average: 0.9 Pharmaceuticals Group Average: 20.8
14.0 32
13.0 30
12.0 28
11.0 26
10.0 24
9.0 22
8.0 20 5-Yr Average
7.0 18
6.0 16
5-Yr Average
5.0 14
4.0 12
2012 2013 2014 2015 2016 2012 2013 2014 2015 2016
FORWARD PE FORWARD PEG

The most recent week's close price divided by the sum of the four The Forward P/E divided by the five-year forecasted growth rate.
upcoming quarterly consensus estimates.
Forward PE: 22.5 Forward PEG: --
5-Year Average: 16.6 5-Year Average: --
FBM KLCI Index Average: 17.8 FBM KLCI Index Average: 2.9
Pharmaceuticals Group Average: 26.6 Pharmaceuticals Group Average: --
39 >5.0
36 4.5
33 4.0
30 3.5
27 3.0
24 2.5 This valuation data is not available
21 2.0
18 1.5
5-Yr Average
15 1.0
12 0.5
9 <0.0
2012 2013 2014 2015 2016 2012 2013 2014 2015 2016
Page 7 of 11
RISK
NEUTRAL OUTLOOK: Moderate risk (medium Risk Score Averages
volatility). Pharmaceuticals Group: 6.7 Small Market Cap: 4.8
Risk Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive HOVID 8 8 7 5 6
KOTRA 9 NR 9 8 6
BIOHLDG 6 5 6 6 5
Negative
FEB-2014 FEB-2015 FEB-2016 FEB-2017
RISK INDICATORS
Magnitude Of Returns Volatility Beta (1-year) Correlation
(25% weight) (25% weight) (25% weight) (25% weight)
BIOHLD
PHARM PHARM
KOTRA
BIOHLD
HOVID KOTRA
HOVID HOVID
KOTRA HOVID
PHARM
KOTRA
BIOHLD PHARM
BIOHLD
RHONE RHONE RHONE RHONE
Daily Returns (Last 90 Days) Standard Deviation Beta vs. FBM KLCI 0.87 Correlation vs. FBM KLCI
Best 4.9% Last 90 Days 2.41 Positive Days Only 1.58 Last 90 Days 30%
Worst -4.8% Last 60 Months 11.19 Negative Days Only 0.19 Last 60 Months 69%
Monthly Returns (Last 60 Months) Intra-Day Swing (Last 90 Days) Beta vs. Group 1.42 Correlation vs. Group
Best 24.2% Average 3.9% Positive Days Only 1.88 Last 90 Days 54%
Worst -22.8% Largest 9.5% Negative Days Only 1.44 Last 60 Months 73%
HIGHLIGHTS RISK ANALYSIS

- Bioalpha Holdings currently has a Risk Rating of 5, which is Last 90 Days Last 60 Months
significantly below the FTSE BURSA MALAYSIA COMPOSITE Best Worst # # Largest Best Worst
index average rating of 9.1. Daily Daily Days Days Intra-Day Monthly Monthly
- On days when the market is up, BIOHLDG tends to outperform Peers Return Return Up Down Swing Return Return
the FTSE BURSA MALAYSIA COMPOSITE index. However, BIOHLDG 4.9% -4.8% 17 21 9.5% 24.2% -22.8%
on days when the market is down, the shares generally
decrease by less than the index. HOVID 5.9% -13.0% 17 20 20.0% 25.7% -16.1%
- In the short term, BIOHLDG has shown average correlation (>= KOTRA -- -- -- -- -- 24.3% -17.7%
0.2 and < 0.4) with the FTSE BURSA MALAYSIA COMPOSITE
index. The stock has, however, shown high correlation (>= 0.4) PHARMA 2.7% -5.0% 17 22 6.5% 89.8% -19.8%
with the market in the long term.
RHONEMA 16.0% -2.2% 12 19 9.2% -- --
- Over the last 90 days, BIOHLDG shares have been more
volatile than the overall market. The stock's daily price FBM KLCI 0.9% -1.1% 34 26 1.3% 4.9% -6.4%
fluctuations have exceeded that of all FTSE BURSA
MALAYSIA COMPOSITE index firms.
Page 8 of 11
PRICE MOMENTUM Currency in MYR
NEUTRAL OUTLOOK: Performance relatively Price Momentum Score Averages

in-line with the market. Pharmaceuticals Group: 6.0 Small Market Cap: 5.3
Price Momentum Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive KOTRA 5 7 NR 4 10
BIOHLDG 8 1 4 4 5
HOVID 5 2 2 2 2
Negative
FEB-2014 FEB-2015 FEB-2016 FEB-2017
PRICE MOMENTUM INDICATORS

Relative Strength Seasonality
(70% weight) (30% weight)
KOTRA
PHARMA
KOTRA BIOHLDG
RHONEMA
HOVID
BIOHLDG
HOVID
PHARMA
RHONEMA
Relative Strength Indicator (Scale from 1 to 100) Average Monthly Return (Last 10 Years)
BIOHLDG Industry Avg FEB MAR APR
Last 1 Month 54 56 Company Avg -1.5% 24.2% -17.7%
Last 3 Months 48 49 Industry Avg 1.6% 4.3% 4.0%
Last 6 Months 49 48 Industry Rank 17 of 54 4 of 54 17 of 54
PRICE PERFORMANCE
Daily close prices are used to calculate the BIOHLDG BIOHLDG FBM KLCI
performance of the stock as compared to a
FBM KLCI Close Price (08/02/17) 0.23 1,689
relevant index over five time periods.
52-Week High 0.33 1,728
0%
1-Week 52-Week Low 0.20 1,615
1%
4.7% - On 08/02/17, BIOHLDG closed at 0.23, 32.6% below its 52-

1-Month
0.8% week high and 15.4% above its 52-week low.
- BIOHLDG shares are currently trading 5.6% above their 50-
-5.1%
3-Month day moving average of 0.21, and 10.7% below their 200-day
1.5% moving average of 0.25.
9.8% - The FTSE BURSA MALAYSIA COMPOSITE index is currently
YTD 2.3% below its 52-week high and 4.6% above its 52-week low.
2.9%
-9.4%
1-Year
1.6%
Page 9 of 11
Mean Estimate Trend

DETAILED STOCK REPORT TIPS The mean estimates show how the consensus has changed over the past 30 days
and 90 days for the upcoming two quarters (when available) and two years. The
The Thomson Reuters Stock Report is a comprehensive, company-specific analysis percentage change is calculated for the company as a means for comparison by
that includes a proprietary Stock Rating along with underlying component indicators measuring the difference between the current consensus estimate and that of 90
and supportive data elements. The report is updated daily, although some of the days ago.
data elements and the ratings are updated weekly.
Analyst Recommendations
Average Score The I/B/E/S Mean is the mean recommendation of all analysts covering the stock,
The Average Score combines a quantitative analysis of five widely-used investment as provided by Thomson Reuters I/B/E/S (Institutional Brokers Estimate System).
decision making tools - Earnings, Fundamental, Relative Valuation, Risk, and Price The recommendations are presented on a five-point standardized scale: strong buy,
Momentum. First, a simple average of the five underlying component ratings is buy, hold, reduce, and sell.
calculated. Then, a normal distribution is used to rank each stock across the market
on a scale of 1 to 10, with 10 being most favorable. A score of 8 to 10 is considered Earnings Surprises
positive, 4 to 7 is neutral, and 1 to 3 is negative. These five factors may be The surprise summary includes the total number of time periods (and
evaluated differently using alternative methodologies, and the importance of percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which
individual factors varies across industry groups, market capitalization and earnings surprises were positive, negative, or in-line. In order to be recognized
investment styles. Additional criteria should always be used to evaluate a stock. as a positive or negative surprise, the percent must be greater than 2% above or
2% below the consensus, respectively.
A company must have sufficient data available for at least three of the five The surprise detail section includes a listing of the company's quarterly earnings
component indicators in order to receive an overall Average Score. Approximately reported for the most recent 6 periods (quarters or years). The consensus
85% of the stocks within the coverage universe meet the criteria to generate a analyst estimate is provided to determine if the actual earnings report
score. represented a positive surprise, negative surprise, or in-line result.
Indicator Components Fundamental
The five indicators that comprise the stock rating are displayed. Like the stock The Fundamental Rating is based on a combination of four fundamental component
rating, the component rating scale is 1 to 10, with 10 being best. A company will factors: profitability, debt, earnings quality, and dividend. Companies that do not
receive an NR for No Rating if the required data elements or criteria are not met. A pay a dividend are not penalized. Each factor is equally weighted. Then, equal
detailed section for each component is included in the report. deciles are used to rank each stock across the market on a scale of 1 to 10, with 10
being most favorable. A stock needs to have at least three of the four fundamental
Indicator Trends factors present in order to receive a score.
Within each component section, historical score trends are displayed, typically using
a 4-week moving average over a timeframe of the past three years. The dotted Profitability is comprised of four data elements.
orange line indicates the average of the scores over those three years. The most - Revenue Growth: (Net Sales Previous Net Sales) / Previous Net Sales
recent occurrences of the best and worst scores are also displayed on the chart in - Gross Margin: Gross Profit / Net Sales
grey boxes to put the current score into historical context. - Return on Equity: Net Income / Total Equity
- Net Margin: Net Profit / Net Sales
Next to the trend chart for the company, current score averages are included, along Debt is comprised of four data elements.
with peer company comparisons of values from 6 months ago, 3 months ago, 1 - Current Ratio: Current Assets / Current Liabilities
month ago, the most recent value from 1 week ago, and the current score. The four - Debt-to-Capital: Total Debt / Total Capital
closest industry peers are presented based on similar market capitalization. - Interest Funding: Interest Expense / Operating Cash Flow
- Interest Coverage: (Pre-Tax Income + Interest Expense) / Interest Expense
Peer Analysis Earnings Quality is comprised of two data elements.
The Thomson Reuters Business Classification (TRBC) system is used for - Days Sales in Inventory: 365 / (Cost of Goods Sold / Inventory)
industry comparisons. It is designed to track and display the primary business of - Days Sales in Receivables: 365 / (Net Sales (Revenues) / Receivables)
a corporation by grouping together correlated companies that offer products and Dividend is comprised of four data elements. The company must have a current
services into similar end markets. The system includes 10 Economic Sectors, 28 dividend yield.
Business Sectors, 54 Industry Groups, and 136 Industries. - Dividend Growth Rate: (Dividends per Share Previous Dividends per Share)
The Peer Analysis section of the report compares the company to its ten closest / Previous Dividends per Share
peers. The peers are selected from the industry based on similar market - Dividend Funding: Dividends / Operating Cash Flow
capitalization. The peer listing may have fewer than ten companies if there are - Dividend Coverage: (Pre-Tax Income + Interest Expense) / (Interest Expense
fewer than ten companies within that industry classification. + Dividends)
- Dividend Yield: Annual Dividends per Share / Current Market Price per Share
Highlights
The Thomson Reuters proprietary automated text-generation system creates Indicator Trend
highlights summarizing the most noteworthy data. The bullets will vary by company The fundamental indicator trend displays either quarterly scores over the past three
and will change from week to week as different criteria are met. years or annual scores over the past six years, depending on the reporting periods
for the country. The best and worst scores can be easily determined from the
Earnings values shown on the chart for each quarter or year.
The Earnings Rating is based on a combination of three factors: earnings surprise,
estimate revision, and recommendation changes. Each factor is equally weighted. Relative Valuation
Then, equal deciles are used to rank each stock across the market on a scale of 1 The Relative Valuation Rating is based on a combination of three component
to 10, with 10 being most favorable. A stock needs to have at least two of the three factors: Price to Sales (50% weight), Trailing P/E (25% weight), and Forward P/E
earnings factors in order to receive a score. (25% weight). After the weightings are considered to combine individual factors,
equal deciles are used to rank each stock across the market on a scale of 1 to 10,
Earnings Surprises - The number of positive and negative surprises within the with 10 being most favorable. These common valuation metrics are evaluated
last 4 periods (quarters or years). against the overall market, the index, and the company's own historic 5-year
Estimate Revisions - The number of up and down revisions and the average averages. A stock needs to have at least one of the three relative valuation factors
percentage change of those revisions within a 4 week period. in order to receive a score.
Recommendation Changes - The number of broker upgrades and downgrades in
the last 120 days. Price to Sales: Close Price / (Sales for 4 Quarters or 1 Year / Shares
Outstanding)
Price Target Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings
The price target is based on the predictions of analysts covering the stock and Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings
shows the high, low and mean price expected within the next 12 months.
Valuation Averages
Earnings Per Share Negative values are excluded when calculating the averages. A maximum value of
The quarterly and annual earnings per share are presented when available, along 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on
with the mean, high and low. Quarterly data is displayed for the past 4 quarters Forward PEG, and a maximum value of 20 is placed on Price to Sales when
(actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2 calculating the averages. Higher values are rounded down to the maximum for the
years (actual) and the next 2 years (estimated). averages.
Page 10 of 11
Valuation Multiples
The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and
Price to Sales for the company and the S&P 500 index average. In addition, a
comparison of the current companys values to its 5-year average and an industry
average are presented. A discount occurs when the companys ratio is valued more
favorably (lower) than that to which it is compared.
Risk
The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the
least risky stocks. It is derived by looking at a series of long-term (5-year) and
short-term (90-day) stock performance measures including volatility, magnitude of
returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles
are used to rank each stock across the market. A stock needs to have at least two
of the four risk factors in order to receive a score.
Magnitude of Returns The best / worst daily returns in the past 90 days and the
best / worst monthly returns in the past 60 months.
Volatility The standard deviation of the stock price over the last 90 days and
last 60 months, along with the average and largest intra-day stock swing.
Beta Measures the tendency of a securitys returns to respond to swings in the
market, based on the beta of the company versus the relevant index.
Correlation Determines how closely the returns of the stock and the relevant
index move together, measured over the last 90 days and last 60 months.
Risk Analysis
Price analysis for the company and the relevant index is provided over two time
periods. Daily analysis is provided for the last 90 days, whereas monthly statistics
are used for the last 60 months.
Price Momentum
The Price Momentum Rating is based on a combination of two technical
performance factors: relative strength (70% weight) and seasonality (30% weight).
After the weightings are considered to combine individual factors, equal deciles are
used to rank each stock across the market on a scale of 1 to 10, with 10 being most
favorable. A stock needs to have data for the relative strength factor in order to
receive a score.
Relative Strength The relative strength of the company for the last 1 month, 3
months, and 6 months on a scale of 1 to 100.
Seasonality The average monthly return (price performance) for the current
month and next 2 months for the company and industry, over the past 10 years.
A lower industry rank indicates a higher return.
Price Performance
Daily close prices are used to calculate the price performance of the stock. The
performance of the relevant index is also displayed as a means of comparison.
DISCLAIMER
Thomson Reuters content (TR Content) is the intellectual property of Thomson
Reuters or its third party content providers. The copying, republication or
redistribution of TR Content, including by framing or similar means is expressly
prohibited without the prior written consent of Thomson Reuters. The TR content in
this report does not constitute a recommendation to buy or sell securities of any kind
or constitute investment advice. Past performance is not a guarantee of future
results.
All information in this report is assumed to be accurate to the best of our ability.
Thomson Reuters excludes all liability, to the maximum extent permitted by law, for
any inaccuracies in the TR Content or for the consequences of your reliance on the
TR Content. Investors should consider this report as only a single factor when
making an investment decision.
Page 11 of 11

AlphaIndicator BIOA 20170209 PDF

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

AlphaIndicator BIOA 20170209 PDF

Încărcat de

Drepturi de autor:

Formate disponibile

BIOALPHA HOLDINGS (BIOHLDG-KU)

Pharma. & Med. Research / Pharmaceuticals / Pharmaceuticals DETAILED STOCK REPORT

HIGHLIGHTS THOMSON REUTERS I/B/E/S MEAN

PRICE AND VOLUME CHARTS

Earnings Fundamental Relative Valuation Risk Price Momentum

PEER ANALYSIS Currency in MYR

PRICE MOMENTUM VALUATION FUNDAMENTAL ANALYSTS

EARNINGS Currency in MYR

BIOHLDG KOTRA BIOHLDG

Last 4 Quarters Last 4 Weeks Last 120 Days

HIGHLIGHTS PRICE TARGET

EARNINGS PER SHARE

Earnings per share (EPS) is calculated Quarterly NA NA

The charts provide a comparison NA NA NA NA

0.021 HIGH Annual 2016 2017

MEAN ESTIMATE TREND ANALYST RECOMMENDATIONS

BIOHLD HOVID HOVID

RHONE RHONE RHONE KOTRA

RELATIVE VALUATION INDICATORS

RHONEMA RHONEMA KOTRA

Price to Sales 5.4 Trailing PE 15.7 Forward PE 22.5

PRICE TO SALES TRAILING PE

FORWARD PE FORWARD PEG

RHONE RHONE RHONE RHONE

HIGHLIGHTS RISK ANALYSIS

PRICE MOMENTUM Currency in MYR

NEUTRAL OUTLOOK: Performance relatively Price Momentum Score Averages

PRICE MOMENTUM INDICATORS

4.7% - On 08/02/17, BIOHLDG closed at 0.23, 32.6% below its 52-

Mean Estimate Trend

S-ar putea să vă placă și